TEST:

One-Step Nucleic Acid Amplification (OSNA) Assay

Sentinel lymph node assessment using one-step nucleic acid amplification and conventional immunohistochemistry ultrastaging did not show significant differences in accuracy for detecting nodal metastases and yielded comparable oncological outcomes, both in overall and disease -free survival. These findings reflect real-world clinical practice, supporting the reliability of both techniques for endometrial cancer staging and suggesting that the choice of sentinel lymph node evaluation method does not affect long-term patient outcomes.

We used our predictive nomogram, including the OSNA factor for patients with positive SLNs, to make decisions regarding ALND and determine the probability of four or more axillary lymph node metastases. Of the 392 patients, 124 (31.3%) had one or two metastases to the SLNs, and 31 (25.0%) had a predictive probability of a nomogram for metastasis to non-SLNs (.

Assessment of tumor-derived mutated DNA in SNs may be a useful technique to detect SN metastasis, as confirmed by ddPCR analysis. Further analyses, using data from a greater number of patients, are necessary to determine whether the results of whole-genome and whole-exome sequencing can be applied to other genes.

Four years of accrual, with estimated results to be presented in 2029. The trial is registered at ClinicalTrials.gov (NCT06935305).